Research & Development
ThinkCyte, Sysmex, Juntendo University partner on chronic myelogenous leukemia research
The collaborative team has been developing approaches to characterize CML-specific morphological differences between blood cancer cells and normal white blood cells using Ghost Cytometry.
April 18, 2023
Blood test identifies acute myeloid leukemia patients at greater risk of relapse
According to a study, patients in remission from acute myeloid leukemia who have residual detectable mutations have higher relapse rates after bone marrow transplants.
March 8, 2023
Scopio digital platform enables bone marrow aspirate imaging
Bone marrow aspirates are normally conducted manually, using microscopic analysis of cells to diagnose cancers such as leukemia and multiple myeloma.
September 7, 2022
Thermo Fisher develops NGS assay for myeloid MRD research
Among the first NGS-based tests to support both DNA and RNA input, the research-use-only Ion Torrent Oncomine Myeloid MRD Assay provides an MRD assessment from blood and bone marrow samples, Thermo Fisher said.
August 3, 2022
SeekIn receives CE Mark for karyotyping kit
Designed to show copy number alteration patterns in leukemia patients based on shallow whole-genome sequencing, the test can help hematologists make diagnoses and prognostic decisions based on European Leukemia Net, Revised International Prognostic Scoring System, or Revised International Staging System guidelines, according to the vendor.
April 6, 2022
Genialis partners with OncXerna to improve targeted therapy
Genialis' ResponderID will use OncXerna's XernaTME (tumor microenvironment) panel to incorporate the pancancer tumor microenvironment classifier to investigate potentially hundreds of new use cases for personalized therapeutic selection.
April 5, 2022
Video from ASH 2021: Advances in treating myeloid disorders
Sekeres is chief of the division of hematology at the Sylvester Comprehensive Cancer Center in Miami. He also serves as ASH's communications director. Sekeres' research interests are in leukemias, myelodysplastic syndromes, and myeloid malignancies.
December 14, 2021
Sysmex develops new leukemia liquid biopsy test
The new test, AML-MRD-SEQ, uses a targeted next generation sequencing (NGS) panel, which covers 68 regions across 20 genes, including established MRD markers such as NPM1.
October 19, 2021
Third Opinion touts AI disease detection results
The patented software achieved a median accuracy of 83.8% for classifying 70 types of blood cells and detected 35 out of 70 specific types of blood cells, the company said. It had a 95% accuracy rate in detection of the 35 most common cells for different types of leukemia.
July 1, 2021
NuProbe introduces pancancer liquid biopsy test
Driven by the company's proprietary blocker displacement amplification technology, the test can detect and quantitate over 6,500 mutations and indels in 61 clinically relevant genes, according to the company. The high sensitivity possible with the product is suitable for detection of minimal residual disease in acute myeloid leukemia and other diseases, NuProbe said in a statement.
February 21, 2021
Thermo Fisher debuts hematology/oncology assays
The Oncomine Myeloid Assay Gx is designed for Thermo Fisher's Ion Torrent Genexus system. The assay also enables researchers to profile 40 DNA targets and 29 fusion driver genes; this enables the detection of more than 600 fusion isotypes for identifying biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia, and myelodysplastic syndrome.
August 18, 2020
Thermo Fisher debuts infectious disease quality controls
The Thermo Scientific Mas Omni Infectious positive and negative quality controls are third-party, independent external controls used to assess the performance of serological assays for HIV types 1 and 2, hepatitis B and C, syphilis, and human T-cell leukemia virus types 1 and 2. Monitoring the assays' performance can streamline operations and may reduce spending without sacrificing quality, according to the company.
June 30, 2020
Page 1 of 2